# Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

> **NCT01233960** · PHASE3 · COMPLETED · sponsor: **Mesoblast, Inc.** · enrollment: 73 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Prochymal®

## Key facts

- **NCT ID:** NCT01233960
- **Lead sponsor:** Mesoblast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-29
- **Primary completion:** 2014-09-15
- **Final completion:** 2014-09-15
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233960, "Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01233960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*